MeSH D056587 - cryopyrin-associated periodic syndromes
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D056660:Hereditary autoinflammatory diseases
0 Companies
0 Drugs
Success rate
D000094482:Chronic inducible urticaria
0 Companies
0 Drugs
Success rate
D000096703:Cold urticaria
0 Companies
0 Drugs
Success rate
D056587:
Cryopyrin-associated periodic syndromes
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Novartis | Canakinumab | Ilaris | 2009-06-17 | $1,038 M | Q2/20-Q2/23 | |
| Orphan Medical | Anakinra | Kineret | 2001-11-14 | |||
| Regeneron Pharmaceuticals | Rilonacept | Rilonacept Regeneron (previously Arcalyst) | 2009-10-23 |
Clinical Trials
Historical Success Rate
Phase 1
50%1/2
Phase 2
33%1/3
Phase 3
100%6/6
Approved: 4Overall Success rate: 17%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use